TY  - JOUR
AU  - Nyssen, Olga P
AU  - Vaira, Dino
AU  - Saracino, Ilaria Maria
AU  - Fiorini, Giulia
AU  - Caldas, María
AU  - Bujanda, Luis
AU  - Pellicano, Rinaldo
AU  - Keco-Huerga, Alma
AU  - Pabon-Carrasco, Manuel
AU  - Oblitas Susanibar, Elida
AU  - Di Leo, Alfredo
AU  - Losurdo, Giuseppe
AU  - Pérez-Aísa, Ángeles
AU  - Gasbarrini, Antonio
AU  - Boltin, Doron
AU  - Smith, Sinead
AU  - Phull, Perminder
AU  - Rokkas, Theodore
AU  - Lamarque, Dominique
AU  - Cano-Català, Anna
AU  - Puig, Ignasi
AU  - Mégraud, Francis
AU  - O'Morain, Colm
AU  - Gisbert, Javier P
PY  - 2022
DO  - 10.3390/jcm11061658
SN  - 2077-0383
UR  - http://hdl.handle.net/10668/21257
T2  - Journal of clinical medicine
AB  - First-line Helicobacter pylori (H. pylori) treatments have been relatively well evaluated; however, it remains necessary to identify the most effective rescue treatments. Our aim was to assess the effectiveness and safety of H. pylori regimens...
LA  - en
KW  - H. pylori
KW  - Helicobacter pylori
KW  - Hp-EuReg
KW  - bismuth
KW  - culture
KW  - eradication failure
KW  - rescue
KW  - rifabutin
KW  - treatment
KW  - Helicobacter pylori
KW  - Rifabutin
KW  - Anti-Bacterial Agents
KW  - Proton Pump Inhibitors
KW  - Drug Resistance, Bacterial
TI  - Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg).
TY  - research article
VL  - 11
ER  -